The melanocortin system
The melanocortin peptides — α-MSH, β-MSH, γ-MSH, and adrenocorticotropic hormone (ACTH) — are derived by proteolytic processing of the pro-opiomelanocortin (POMC) precursor. They signal through a family of five G-protein-coupled receptors (MC1R through MC5R), each with distinct tissue distribution and physiological role. MC1R is expressed on melanocytes and regulates pigmentation. MC2R is the ACTH receptor of the adrenal cortex. MC3R and MC4R are enriched in the central nervous system and regulate feeding, energy balance, and — of relevance here — components of sexual response. MC5R has roles in exocrine glands.
The shared endogenous ligand element across MC1R, MC3R, MC4R, and MC5R is the core sequence His-Phe-Arg-Trp, present in α-MSH. Most synthetic melanocortin agonists — including Melanotan-II and PT-141 — retain this pharmacophore in a constrained backbone.
From Melanotan-II to PT-141
Melanotan-II is a cyclic heptapeptide analog of α-MSH developed as a potent agonist across multiple melanocortin receptors, characterised in early studies for its skin-pigmentation activity via MC1R and its central effects via MC3R/MC4R. Its broad receptor engagement made it a useful pharmacological probe but complicated efforts to isolate specific effects.
PT-141 was derived from Melanotan-II by removal of the C-terminal amide residue that contributed to MC1R engagement and pigmentation. The result is a molecule with a pharmacological profile more focused on MC3R and MC4R activity, particularly the CNS effects mediated by MC4R. In the preclinical literature this shift is used to separate the pigmentary from the neural effects that both peptides share their lineage with.
Receptor pharmacology
In binding and functional assays, PT-141 is characterised as an agonist across MC3R, MC4R, and MC5R, with the MC4R activity generally considered the most relevant to the endpoints studied in vivo. MC4R activation couples primarily to Gαs and elevation of intracellular cAMP.
Downstream of MC4R activation, preclinical work has traced signalling through hypothalamic and other CNS structures, with sexual-response endpoints in animal models used as the primary functional readouts. The receptor engagement is not selective — PT-141 hits multiple melanocortin receptors — but MC4R is the axis most closely tied to the endpoints of interest in the peptide's characterisation.
Preclinical models of sexual response
In male rodent models, published preclinical work has assessed erectile-response and copulatory endpoints following melanocortin-agonist administration. In female rodent models, endpoints have included proceptive and receptive behaviours characterised in operant paradigms — a distinction from vasoactive pathways that has been used to frame melanocortin agonism as CNS-mediated rather than direct peripheral vasodilation.
The animal-model literature framed the mechanistic hypothesis subsequently pursued in later development work. From a research-methods standpoint, the endpoints are behavioural or physiological readouts specific to the animal model — not translatable to human use guidance.
Peripheral effects and pharmacokinetics
Melanocortin-receptor agonism has peripheral effects worth noting in a preclinical characterisation. Transient elevations in blood pressure and modest reductions in heart rate have been reported at higher exposures. Residual MC1R activity — reduced but not eliminated relative to Melanotan-II — can produce pigmentary effects in prolonged animal exposure, though these are much less pronounced than with the parent compound.
Pharmacokinetic characterisation includes plasma half-life measurements, subcutaneous absorption profiles, and tissue distribution — parameters that inform exposure regimens in animal-model studies but are strictly research-context measurements.
Route of administration in preclinical work
PT-141 has been characterised across multiple administration routes in the preclinical literature. Subcutaneous administration is the reference route in most animal work; it produces reproducible plasma exposure profiles and is compatible with the pharmacokinetic characterisation of a cyclic peptide of PT-141's size.
Intranasal administration was an early alternative studied for its non-invasive delivery profile. Preclinical and early human pharmacokinetic work compared intranasal absorption against subcutaneous reference, characterising bioavailability, time-to-peak, and inter-subject variability. Intranasal delivery was subsequently deprioritised in the development pathway, but the comparative work remains a useful case study in peptide-formulation pharmacokinetics.
For animal studies, the choice of route matters mechanistically as well as pharmacokinetically. Direct central administration — intracerebroventricular in rodent models — has been used to distinguish central from peripheral receptor engagement, an important design element in interpreting behavioural endpoints. The blood–brain barrier is only partially permeable to PT-141 by peripheral routes; centrally administered peptide bypasses this constraint.
For research protocols in general, the route should be matched to the endpoint. Peripheral routes are appropriate when the question is systemic exposure and receptor engagement across compartments; central routes are used when the question is specific engagement of CNS melanocortin receptors in the absence of peripheral confounding.
Comparative context: PT-141, Melanotan-II, and setmelanotide
In the melanocortin-agonist landscape, PT-141 sits between the broadly-active Melanotan-II and the highly-selective MC4R agonist setmelanotide. Melanotan-II retains stronger MC1R activity and the associated pigmentary effects. Setmelanotide (a later compound) was engineered for much greater MC4R selectivity, focused on obesity research. Comparing the three illustrates how backbone modifications translate into receptor-selectivity differences within the same peptide family.
Analytical characterisation and storage
PT-141 is characterised by mass spectrometry for identity and reversed-phase HPLC for purity. As a cyclic peptide with a lactam bridge, characterisation methods should be tuned to resolve the cyclic species from any linear precursor or ring-opened impurities.
Lyophilised material is stored sealed and cold, and reconstituted material is refrigerated and aliquotted into single-use portions to minimise freeze-thaw exposure. As with any research peptide, working-concentration stability should be characterised in the specific buffer system used in a given study.
Worked examples
Reconstituting a 10 mg PT-141 vial
- 01Bring the sealed vial to room temperature before opening.
- 02Wipe the stopper with an alcohol swab.
- 03Add 2 mL of bacteriostatic water for a nominal 5 mg/mL working concentration.
- 04Let the diluent run down the inside wall of the vial. Do not spray onto the solid.
- 05Swirl gently until dissolved. Do not shake.
- 06Label with lot, concentration, diluent, and reconstitution date.
Storage protocol for a multi-week study
- 01Lyophilised material: sealed and desiccated at 2–8 °C for short-term storage; −20 °C for longer-term storage.
- 02Reconstituted material: refrigerated at 2–8 °C, aliquotted into single-use portions to minimise freeze-thaw exposure.
- 03Label every aliquot with lot, concentration, and date.
- 04Track freeze-thaw cycles per aliquot; treat any aliquot cycled repeatedly as an unknown until re-characterised.
Frequently asked questions
How was PT-141 derived from Melanotan-II?
PT-141 is Melanotan-II with the C-terminal amide residue removed. That truncation reduces MC1R engagement — and the pigmentary effects associated with it — while retaining activity at MC3R, MC4R, and MC5R. The result is a pharmacological profile more focused on the CNS-mediated endpoints of interest.
Which melanocortin receptor drives the preclinical endpoints of interest?
MC4R is generally considered the receptor most relevant to the sexual-response endpoints observed in animal models. PT-141 is not MC4R-selective — it also engages MC3R and MC5R — but MC4R is the axis most closely tied to the observed endpoints.
Does PT-141 cause pigmentation like Melanotan-II?
Residual MC1R activity is present, so pigmentary effects are not eliminated — but they are substantially reduced relative to Melanotan-II because of the structural change. The magnitude depends on cumulative exposure and the model system.
What analytical tests confirm identity and purity?
Reversed-phase HPLC quantifies purity, and mass spectrometry confirms identity against the expected molecular weight. Because PT-141 is a cyclic peptide, characterisation methods should be tuned to resolve the cyclic species from any linear precursor or ring-opened impurity.
How should reconstituted PT-141 be stored?
Refrigerated at 2–8 °C, aliquotted into single-use portions to minimise freeze-thaw exposure, and characterised in the specific buffer system used for a given study.
References
Selected published research referenced in this article.
- 01Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96–102. PubMed
- 02Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to sildenafil. Int J Impot Res. 2004;16(2):135–142. PubMed
- 03Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51–59. PubMed
- 04Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101(27):10201–10204. PubMed
- 05Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389–393. PubMed
- 06Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27(7):736–749. PubMed